Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
125
-
Total 13F shares, excl. options
-
33.4M
-
Shares change
-
+1.52M
-
Total reported value, excl. options
-
$497M
-
Value change
-
+$18.7M
-
Number of buys
-
74
-
Number of sells
-
-49
-
Price
-
$14.87
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2017
147 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2017.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 125 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.4M shares
of 236M outstanding shares and own 14.15% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.91M shares), EAGLE ASSET MANAGEMENT INC (2.72M shares), Novo Holdings A/S (2.23M shares), CARILLON TOWER ADVISERS, INC. (2.06M shares), PERCEPTIVE ADVISORS LLC (1.99M shares), Vanguard Group Inc (1.94M shares), Nantahala Capital Management, LLC (1.93M shares), RENAISSANCE TECHNOLOGIES LLC (1.82M shares), STATE STREET CORP (1.49M shares), and MILLENNIUM MANAGEMENT LLC (1.02M shares).
This table shows the top 125 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.